These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 12478709)
21. Are patent expirations the answer to improving patient adherence? Klepser DG Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495 [No Abstract] [Full Text] [Related]
22. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
23. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
24. [Free trade agreements make the drugs more expensive]. Jeppsson A Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499 [No Abstract] [Full Text] [Related]
25. Statin utilisation--recognising the role of the invisible hand. Minhas R Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171 [No Abstract] [Full Text] [Related]
26. Going over the patent cliff. Schommer JC Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283 [No Abstract] [Full Text] [Related]
27. Watch for these new generics. Consum Rep; 2012 May; 77(5):12. PubMed ID: 22641866 [No Abstract] [Full Text] [Related]
28. Patent indicators: a window to pharmaceutical market success. Guo Y; Hu Y; Zheng M; Wang Y Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022 [TBL] [Abstract][Full Text] [Related]
29. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere. Baker BK PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325 [TBL] [Abstract][Full Text] [Related]
30. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
31. Generic drug stocks: don't get hooked. McLean B Fortune; 2000 Oct; 142(10):250. PubMed ID: 11184821 [No Abstract] [Full Text] [Related]
33. NHS spending on drugs is frozen for two years under price deal. Wise J BMJ; 2013 Nov; 347():f6731. PubMed ID: 24201064 [No Abstract] [Full Text] [Related]
34. US policy may encourage counterfeit drugs. Bouchie A Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826 [No Abstract] [Full Text] [Related]
35. White paper. The five myths of generic competition. A Pharma Matters report. March 2009. Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560 [TBL] [Abstract][Full Text] [Related]
36. [Patients, patents and profits]. Roland PC Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741 [No Abstract] [Full Text] [Related]
37. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments. Yvon AM Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596 [No Abstract] [Full Text] [Related]
38. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]